课题基金 / 基金详情

CONTRIBUTION OF INTESTINAL CYP3A TO FIRST PASS METABOLISM OF MIDAZOLAM

CONTRIBUTION OF INTESTINAL CYP3A TO FIRST PASS METABOLISM OF MIDAZOLAM
肠道 CYP3A 对咪达唑仑首过代谢的贡献
批准号：
6117753
负责人：
D CRAIG BRATER
金额：
$1.7万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6117753
关键词：
clarithromycin clinical research cytochrome P450 drug metabolism human subject intravenous administration midazolam oral administration pharmacokinetics

项目摘要

项目成果

D CRAIG BRATER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
A goal of this study is to determine the contribution of intestinal cytochrome P450 3A to the observed first-pass metabolism of midazolam following oral administration using silmultaneous intravenous and oral administration of midazolam and a stable isotope (N-midazolam). A second goal of the study is to determine if clarithromycin inhibits the metabolism of midazolam following oral administration at the intestinal or hepatic level.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Diuretics on Response to Torsemide in Patients with Congestive Heart Failure
General Clinical Research Ctr:Pharmacogenetics Core Supp
MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE
MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE
海外基金